Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection
The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of SARS-CoV-2 at a giv...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/6/1318 |
| _version_ | 1797540396185681920 |
|---|---|
| author | Marianne Riou Walid Oulehri Cedric Momas Olivier Rouyer Fabienne Lebourg Alain Meyer Irina Enache Cristina Pistea Anne Charloux Christophe Marcot Frederic de Blay Olivier Collange Michel Mertes Emmanuel Andrès Samy Talha Bernard Geny |
| author_facet | Marianne Riou Walid Oulehri Cedric Momas Olivier Rouyer Fabienne Lebourg Alain Meyer Irina Enache Cristina Pistea Anne Charloux Christophe Marcot Frederic de Blay Olivier Collange Michel Mertes Emmanuel Andrès Samy Talha Bernard Geny |
| author_sort | Marianne Riou |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of SARS-CoV-2 at a given distance from the acute infection is largely unknown. We assessed brachial artery flow-mediated dilatation (FMD) in 27 COVID-19 patients needing conventional or intensive care unit hospitalization, three months after SARS-CoV-2 infection diagnosis and in nine age- and sex- matched control subjects. Interestingly, the FMD was lower in COVID-19 patients as compared to controls (8.2 (7.2–8.9) vs. 10.3 (9.1–11.7)); <i>p</i> = 0.002, and half of the hospitalized COVID-19 survivors presented with a reduced FMD < 8% at three months of COVID-19 onset. Impaired FMD was not associated with severe or critical SARS-CoV-2 infection, reflected by ICU hospitalization, total hospitalization duration, or severity of lung damage. In conclusion, reduced FMD is often observed even three months after hospitalization for SARS-CoV-2 infection, but such alteration predominantly appears to not be related to COVID-19 severity. Longer and larger follow-up studies will help to clarify the potential prognosis value of FMD among COVID-19 patients, as well as to further determine the mechanisms involved. |
| first_indexed | 2024-03-10T13:00:31Z |
| format | Article |
| id | doaj.art-f5cbeeda2b304dde9949db3c96d40fa4 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T13:00:31Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f5cbeeda2b304dde9949db3c96d40fa42023-11-21T11:37:27ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-01106131810.3390/jcm10061318Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 InfectionMarianne Riou0Walid Oulehri1Cedric Momas2Olivier Rouyer3Fabienne Lebourg4Alain Meyer5Irina Enache6Cristina Pistea7Anne Charloux8Christophe Marcot9Frederic de Blay10Olivier Collange11Michel Mertes12Emmanuel Andrès13Samy Talha14Bernard Geny15Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FrancePhysiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FrancePhysiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceDepartment of Pneumology, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceTeam 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, FranceThe coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of SARS-CoV-2 at a given distance from the acute infection is largely unknown. We assessed brachial artery flow-mediated dilatation (FMD) in 27 COVID-19 patients needing conventional or intensive care unit hospitalization, three months after SARS-CoV-2 infection diagnosis and in nine age- and sex- matched control subjects. Interestingly, the FMD was lower in COVID-19 patients as compared to controls (8.2 (7.2–8.9) vs. 10.3 (9.1–11.7)); <i>p</i> = 0.002, and half of the hospitalized COVID-19 survivors presented with a reduced FMD < 8% at three months of COVID-19 onset. Impaired FMD was not associated with severe or critical SARS-CoV-2 infection, reflected by ICU hospitalization, total hospitalization duration, or severity of lung damage. In conclusion, reduced FMD is often observed even three months after hospitalization for SARS-CoV-2 infection, but such alteration predominantly appears to not be related to COVID-19 severity. Longer and larger follow-up studies will help to clarify the potential prognosis value of FMD among COVID-19 patients, as well as to further determine the mechanisms involved.https://www.mdpi.com/2077-0383/10/6/1318COVID-19vascular functionflow-mediated dilatation |
| spellingShingle | Marianne Riou Walid Oulehri Cedric Momas Olivier Rouyer Fabienne Lebourg Alain Meyer Irina Enache Cristina Pistea Anne Charloux Christophe Marcot Frederic de Blay Olivier Collange Michel Mertes Emmanuel Andrès Samy Talha Bernard Geny Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection Journal of Clinical Medicine COVID-19 vascular function flow-mediated dilatation |
| title | Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection |
| title_full | Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection |
| title_fullStr | Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection |
| title_full_unstemmed | Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection |
| title_short | Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection |
| title_sort | reduced flow mediated dilatation is not related to covid 19 severity three months after hospitalization for sars cov 2 infection |
| topic | COVID-19 vascular function flow-mediated dilatation |
| url | https://www.mdpi.com/2077-0383/10/6/1318 |
| work_keys_str_mv | AT marianneriou reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT walidoulehri reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT cedricmomas reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT olivierrouyer reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT fabiennelebourg reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT alainmeyer reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT irinaenache reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT cristinapistea reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT annecharloux reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT christophemarcot reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT fredericdeblay reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT oliviercollange reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT michelmertes reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT emmanuelandres reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT samytalha reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection AT bernardgeny reducedflowmediateddilatationisnotrelatedtocovid19severitythreemonthsafterhospitalizationforsarscov2infection |